View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 13, 2011

Teva Completes Taiyo Acquisition

Israel-based Teva Pharmaceuticals has completed the acquisition of Taiyo Pharmaceutical Industry, Japan's third largest generics company, for $934m. Taiyo generated $530m in sales in 2010 and brings a portfolio containing in excess of 550 products to Teva, with Teva now expecting sales

By cms admin

Israel-based Teva Pharmaceuticals has completed the acquisition of Taiyo Pharmaceutical Industry, Japan’s third largest generics company, for $934m.

Taiyo generated $530m in sales in 2010 and brings a portfolio containing in excess of 550 products to Teva, with Teva now expecting sales in the region to reach $1bn.

Teva will also inherit Taiyo’s R&D team and production facility, and will also benefitting from the company’s knowledge of local regulatory systems.

Teva president and CEO Shlomo Yanai said: “The acquisition of Taiyo, along with Teva’s existing Japanese business, assures that Teva will deliver on our strategic objective of becoming a leading player in Japan.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology